Drug Insights

Unlock the Power of Synapse: A Guide to Searching Hydrocortisone

15 March 2024
2 min read

Hydrocortisone, a diminutive yet powerful molecule, is renowned for its aptitude to function as a glucocorticoid receptor (GR) agonist, thereby stimulating the GR. This drug boasts a diverse range of clinical applications and is typically employed in the treatment of a multitude of ailments that are closely associated with adrenal insufficiency, including but not limited to congenital adrenal hyperplasia, adrenal hyperplasia, Addison's disease, and isolated ACTH deficiency. Additionally, it has proven efficacious in treating inflammatory conditions such as subacute thyroiditis, ulcerative colitis, proctocolitis, and ulcerative proctitis. It is worth noting that the FDA initially granted its approval to hydrocortisone on the 5th of August, 1952. The development of hydrocortisone is credited to Merck Sharp & Dohme Corp, which pioneered the drug. Owing to its extraordinary anti-inflammatory and immunosuppressive qualities, hydrocortisone has emerged as a definitive remedy for numerous chronic inflammatory disorders. Click on the image below to begin the exploration journey of Hydrocortisone through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

AbilityPharma Receives €7M for Phase 2b Trials of Cancer Drug ABTL0812
Latest Hotspot
3 min read
AbilityPharma Receives €7M for Phase 2b Trials of Cancer Drug ABTL0812
15 March 2024
AbilityPharma Secures Funding of €7M for Progressing Phase 2b Trials of ABTL0812, an Autophagy-Stimulating Drug, in Treating Spread-Out Pancreatic Cancer.
Read →
A Century of Innovation and Growth at Novo Nordisk
R&D Pipeline
8 min read
A Century of Innovation and Growth at Novo Nordisk
15 March 2024
Novo Nordisk has excelled in research and development, aiding over 40 million chronic disease patients globally.
Read →
Ranok Therapeutics Expands RNK05047 Clinical Trials to China
Latest Hotspot
3 min read
Ranok Therapeutics Expands RNK05047 Clinical Trials to China
15 March 2024
Ranok Therapeutics broadens its clinical trials for its BRD4 protein degradation agent RNK05047, now including tests in China.
Read →
How to Effectively Search for Budesonide on Synapse
Drug Insights
2 min read
How to Effectively Search for Budesonide on Synapse
15 March 2024
Budesonide, a small molecule drug with a strong ability to bind to the glucocorticoid receptor (GR) as an agonist, was approved as early as 1981 and has been on the market for more than 40 years.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.